Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III–IV lung cancer

吡柔比星 医学 肺癌 临床终点 内科学 肝细胞癌 胃肠病学 不利影响 化疗 外科 随机对照试验
作者
Yonghua Bi,Xiaonan Shi,Mengfei Yi,Xinwei Han,Jianzhuang Ren
出处
期刊:Acta Radiologica [SAGE Publishing]
卷期号:63 (3): 311-318 被引量:29
标识
DOI:10.1177/0284185121994298
摘要

Background CalliSpheres® beads (CB) have been used recently for patients with hepatocellular carcinoma. However, the safety and effect of drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with stage III–IV lung cancer are still unknown. Purpose To evaluate the safety and efficacy of DEB-TACE with pirarubicin-loaded CB for the treatment of stage III–IV lung cancer. Material and Methods From July 2016 to April 2020, 29 patients with stage III–IV primary lung cancer underwent DEB-TACE with pirarubicin-loaded CB. The objective response rate (ORR) was the primary endpoint; the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results Twenty-nine patients received DEB-TACE with pirarubicin-loaded (median 60 mg) CB, with no severe adverse events or treatment-related deaths. After DEB-TACE, hemoptysis disappeared within 1–3 days in all patients, and the symptoms of cough or expectoration were significantly improved in 12 patients. ORR and disease control rate at one, three, and six months after DEB-TACE were 39.3% and 96.4%, 26.1% and 69.6%, and 29.4% and 58.8%, respectively. The median PFS was 6.3 months (range 1.1–30.1 months), and the three-, six-, and 12-month PFS rates were 70.2%, 50.1%, and 27.1%, respectively. The median OS was 10.2 months (range 1.1–44.6 months), and the three-, six, and 12-month OS rates were 87.9%, 68.6%, and 39.8%, respectively. Conclusion DEB-TACE with pirarubicin-loaded CB is safe, feasible, and well-tolerated for patients with stage III–IV lung cancer, and symptom control was a potential benefit of treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷少完成签到,获得积分10
刚刚
嗷嗷完成签到,获得积分10
刚刚
2秒前
时平谊发布了新的文献求助10
4秒前
二柱子完成签到 ,获得积分10
4秒前
4秒前
Lucky完成签到,获得积分10
6秒前
丘比特的应助被温柔梦易采纳,获得10
6秒前
7秒前
liu完成签到,获得积分10
9秒前
王成鑫完成签到 ,获得积分10
9秒前
时平谊发布了新的文献求助200
10秒前
u924435完成签到,获得积分10
11秒前
北北完成签到 ,获得积分10
11秒前
1212122发布了新的文献求助10
12秒前
活泼的访云完成签到,获得积分10
13秒前
13秒前
鹿呦完成签到 ,获得积分10
14秒前
123完成签到 ,获得积分10
15秒前
promise完成签到 ,获得积分10
15秒前
CH完成签到,获得积分10
16秒前
Richard完成签到,获得积分10
16秒前
陶醉白梅完成签到,获得积分20
16秒前
17秒前
从容的罡完成签到,获得积分10
17秒前
FashionBoy的应助被丁一航采纳,获得10
18秒前
fsy完成签到,获得积分10
18秒前
Prophet发布了新的文献求助10
19秒前
安小安完成签到,获得积分10
19秒前
19秒前
20秒前
无足鸟完成签到,获得积分10
20秒前
21秒前
Samsara完成签到 ,获得积分10
22秒前
执着访文完成签到,获得积分10
22秒前
zr发布了新的文献求助10
23秒前
毅诚菌完成签到,获得积分10
23秒前
阿业发布了新的文献求助10
24秒前
24秒前
无极微光的应助被1212122采纳,获得20
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582